UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 22, 2020
CRYO CELL International, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 000-23386 | 22-3023093 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File No.) |
(I.R.S. Employer Identification No.) | ||
700 Brooker Creek Boulevard, Oldsmar, Florida | 34677 | |||
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (813) 749-2100
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Common Stock, $0.01 par value | CCEL | OTCQB |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 | Submission of Matters to a Vote of Security Holders |
On September 22, 2020, the Company held its Annual Meeting of Stockholders. At the Annual Meeting, stockholders considered the election of five directors, the ratification of the Companys independent registered public accountants and the approval of a non-binding advisory resolution regarding the compensation of the Companys named executive officers in its proxy statement for shareholder consideration.
The final result of the stockholder vote was certified on September 22, 2020 and is as follows:
1. | To consider for election five individuals to the Companys Board of Directors |
Under plurality voting, the five nominees who received the most FOR votes were elected as directors. The Companys stockholders elected the Board of Directors five nominees: Harold Berger; David Portnoy; George Gaines; Jonathan Wheeler, M.D., and Brian Sheehy as directors, each for a one-year term, as follows:
Harold Berger | ||
For |
1,393,331 | |
Withhold |
1,163,186 | |
George Gaines | ||
For |
2,238,776 | |
Withhold |
317,721 | |
David I. Portnoy | ||
For |
1,754,429 | |
Withhold |
802,068 | |
Brian Sheehy | ||
For |
2,201,639 | |
Withhold |
354,858 | |
Jonathan H. Wheeler, M.D. | ||
For |
2,246,488 | |
Withhold |
310,009 |
2. | The ratification of the appointment of WIPFLI LLC as the Companys independent registered public accounting firm for the fiscal year ending November 30, 2020. |
For |
Against |
Abstain |
||||
6,619,468 | 61,354 | 18,869 |
3. | The approval of the Companys non-binding resolution regarding the compensation of the Companys named executive officers. |
For |
Against |
Abstain |
Broker Non-Vote | |||
1,303,954 | 1,245,545 | 6,998 | 4,143,194 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Cryo-Cell International, Inc. | ||||||
DATE: September 23, 2020 | By: | /s/ David Portnoy | ||||
David Portnoy | ||||||
Chairman and Co-Chief Executive Officer |